

Gaucher disease is a multi-systemic disease, with varied patient symptoms manifesting in different organs and progressing over time.¹⁻⁴ The age of onset and the severity of symptoms can vary. The main clinical manifestations are presented in the table.

Clinical manifestation ^{1,5,6}	Definition ^{6,7}	Symptoms and prevalence ⁸
Splenomegaly	Higher than spleen volume of an unaffected person (>0.2% body weight)	Early satiety, abdominal pain or distension ¹ Occurs in 95% of patients ⁹
Thrombocytopenia	Lower than platelet count of an unaffected person (<150 × 10 ⁹ /L)	Bruising, nosebleeds, ⁴ post-operative bleeding
Anemia	Lower than hemoglobin levels of an unaffected person (<140 g/L)	Fatigue Occurs in ~50% of patients ⁹
Hepatomegaly	Higher than liver volume of an unaffected person (>2.5% body weight)	Early satiety, abdominal pain ^{1,9} Occurs in 80% of patients ⁴
Skeletal manifestations		Abnormal bone shaping, bone pain, bone infections, fractures ¹ Occurs in 70–100% of patients ¹

REFERENCES: 1. Guggenbuhl P *et al. Joint Bone Spine.* 2008; 75(2): 116–124. 2. U.S. National Library of Medicine. Gaucher Disease. <https://ghr.nlm.nih.gov/condition/gaucher-disease>. 2014. Accessed June 10, 2020. 3. National Organization for Rare Disorders. The physician's guide to Gaucher disease. <https://rarediseases.org/physician-guide/gaucher-disease/>. Published 2013. Accessed June 10, 2020. 4. Nagral A. *J Clin Exp Hepatol.* 2014; 4(1): 37–50. 5. Mistry PK *et al. Am J Hematol.* 2011; 86(1): 110–115. 6. Mehta A *et al. Intern Med J.* 2019; 49(5): 578–591. 7. Pastores GM *et al. Semin Hematol.* 2004; 41(4 Suppl 5): 4–14. 8. Thomas AS *et al. Br J Haematol.* 2014; 165(4): 427–440. 9. Stirnemann J *et al. Int J Mol Sci.* 2017; 18(2): 441.



©2020 Takeda Pharmaceutical Company Limited. 300 Shire Way, Lexington, MA 02421. 1-800-828-2088. All rights reserved. Takeda and the Takeda logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. US-NON-2035v1.0 09/20